MX2017002052A - Metodos para tratar la depresion usando moduladores de nmda. - Google Patents

Metodos para tratar la depresion usando moduladores de nmda.

Info

Publication number
MX2017002052A
MX2017002052A MX2017002052A MX2017002052A MX2017002052A MX 2017002052 A MX2017002052 A MX 2017002052A MX 2017002052 A MX2017002052 A MX 2017002052A MX 2017002052 A MX2017002052 A MX 2017002052A MX 2017002052 A MX2017002052 A MX 2017002052A
Authority
MX
Mexico
Prior art keywords
methods
treating depression
nmda modulators
nmda
modulators
Prior art date
Application number
MX2017002052A
Other languages
English (en)
Inventor
Burch Ron
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MX2017002052A publication Critical patent/MX2017002052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona métodos y regímenes para tratar la depresión (por ejemplo, depresión resistente al tratamiento) en un paciente (por ejemplo, un paciente que necesita dicho tratamiento).
MX2017002052A 2014-08-14 2015-08-13 Metodos para tratar la depresion usando moduladores de nmda. MX2017002052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14
PCT/US2015/045071 WO2016025721A1 (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Publications (1)

Publication Number Publication Date
MX2017002052A true MX2017002052A (es) 2018-08-15

Family

ID=55304631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002052A MX2017002052A (es) 2014-08-14 2015-08-13 Metodos para tratar la depresion usando moduladores de nmda.

Country Status (18)

Country Link
US (1) US20170296616A1 (es)
EP (1) EP3180015A4 (es)
JP (2) JP2017524721A (es)
KR (1) KR20170040351A (es)
CN (1) CN106659763A (es)
AU (2) AU2015301650A1 (es)
BR (1) BR112017002930A2 (es)
CA (1) CA2957937A1 (es)
CL (1) CL2017000378A1 (es)
CO (1) CO2017002356A2 (es)
IL (1) IL250557A0 (es)
MX (1) MX2017002052A (es)
PH (1) PH12017500275A1 (es)
RU (1) RU2017107033A (es)
SG (2) SG11201701134XA (es)
UA (1) UA123623C2 (es)
WO (1) WO2016025721A1 (es)
ZA (1) ZA201701526B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016340080A1 (en) * 2015-10-16 2018-05-10 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
EP3706734A1 (en) * 2017-11-10 2020-09-16 Naurex Inc. Methods of administration of nmda receptor agonists
BR112020011401A2 (pt) * 2017-12-05 2020-11-24 Naurex Inc. combinação de moduladores de receptor nmda (rapastinel) para uso em tratamento combinado (distúrbio do sono e do snc)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
EP3488856A1 (en) * 2009-10-05 2019-05-29 Northwestern University Methods of treating depression and other related diseases
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
CL2017000378A1 (es) 2017-11-03
ZA201701526B (en) 2018-05-30
JP2017524721A (ja) 2017-08-31
CO2017002356A2 (es) 2017-06-09
AU2020203165A1 (en) 2020-06-04
JP2020128391A (ja) 2020-08-27
BR112017002930A2 (pt) 2017-12-05
UA123623C2 (uk) 2021-05-05
US20170296616A1 (en) 2017-10-19
RU2017107033A (ru) 2018-09-14
SG10201810016XA (en) 2018-12-28
WO2016025721A1 (en) 2016-02-18
CA2957937A1 (en) 2016-02-18
RU2017107033A3 (es) 2019-02-12
IL250557A0 (en) 2017-03-30
EP3180015A4 (en) 2018-02-14
CN106659763A (zh) 2017-05-10
SG11201701134XA (en) 2017-03-30
PH12017500275A1 (en) 2017-07-03
EP3180015A1 (en) 2017-06-21
KR20170040351A (ko) 2017-04-12
AU2015301650A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
PH12018501656A1 (en) Methods for using fxr agonists
NZ731467A (en) Anti-tim3 antibodies and methods of use
HK1219218A1 (zh) 提供牙齒矯治用附件的方法以及該附件
GB2541571A (en) Pharmaceutical compositions
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
IL260684B (en) Treatment to regulate the microbiota in the intestine
IL274855A (en) Device, systems and methods for dental treatments
SG10201900574SA (en) Virtual currency conversion device, method and computer program
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
MX2017002489A (es) Agentes terapeuticos humanos.
EP3122296A4 (en) Ophthalmic treatment solution delivery devices and delivery augmentation methods
IL271728A (en) Materials, uses and treatment methods
MX2017000306A (es) Metodos para tratar hipotension.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12017500602A1 (en) Methods for treating ocular conditions
MX2016009537A (es) Metodo para tratar ropa.
EP3166329A4 (en) White noise generating headset for stress relaxation and concentration improvement, and white noise generating method using same
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
GB2539742B (en) Therapeutic treatment methods, and apparatus for use therein
MX2016009541A (es) Metodo para tratar vajilla.